☆ 4.5 Editorial Material

Inflammatory Markers to Inform Treatment of Asthma With Biologicals: FeNO Versus Blood Eosinophils

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2023)

Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to- Severe Asthma

Ian D. Pavord et al.

Summary: Baseline FeNO levels can serve as a predictive biomarker for treatment response to dupilumab in patients with uncontrolled moderate-to-severe asthma, independent of blood eosinophil levels. Higher baseline FeNO is associated with greater clinical effects of dupilumab, regardless of eosinophil levels.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2023)

添加到收藏夹

Article Critical Care Medicine

Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis

William W. Busse et al.

Summary: In this study, higher baseline FeNO levels were associated with greater risk of severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma, especially when combined with elevated eosinophil count and prior exacerbations, supporting the added value of FeNO as a prognostic biomarker. Further research is needed to confirm FeNO as an independent predictor for asthma exacerbations.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal